{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T18:29:37Z","timestamp":1776882577213,"version":"3.51.2"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,16]]},"DOI":"10.7759\/cureus.15703","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T03:18:57Z","timestamp":1623899937000},"source":"Crossref","is-referenced-by-count":4,"title":["A Case of De Novo Psoriasis Secondary to Nivolumab in a Patient With Metastatic Renal Cell Carcinoma"],"prefix":"10.7759","author":[{"given":"Sanjana","family":"Mullangi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreeja","family":"Ponnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manidhar Reddy","family":"Lekkala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supriya","family":"Koya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1714","article-title":"PD-1 pathway inhibitors: immuno-oncology agents for restoring antitumor immune responses","volume":"36","author":"Medina PJ","year":"2016","unstructured":"Medina PJ, Adams VR. PD-1 pathway inhibitors: immuno-oncology agents for restoring antitumor immune responses. Pharmacotherapy. 2016, 36:317-34. 10.1002\/phar.1714","journal-title":"Pharmacotherapy"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer RJ","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, et al.. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015, 373:1803-13. 10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12876","article-title":"Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy","volume":"44","author":"Vivar KL","year":"2017","unstructured":"Vivar KL, Deschaine M, Messina J, et al.. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017, 44:381-4. 10.1111\/cup.12876","journal-title":"J Cutan Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13336","article-title":"Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma","volume":"30","author":"Kato Y","year":"2016","unstructured":"Kato Y, Otsuka A, Miyachi Y, Kabashima K. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol. 2016, 30:e89-91. 10.1111\/jdv.13336","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","author":"Sibaud V","year":"2016","unstructured":"Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1\/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016, 28:254-63. 10.1097\/CCO.0000000000000290","journal-title":"Curr Opin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: a study of 21 patients","volume":"31","author":"Bonigen J","year":"2017","unstructured":"Bonigen J, Raynaud-Donzel C, Hureaux J, et al.. Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol. 2017, 31:e254-7. 10.1111\/jdv.14011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219877234","article-title":"Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer","volume":"26","author":"Guven DC","year":"2020","unstructured":"Guven DC, Kilickap S, Guner G, Taban H, Dizdar O. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer. J Oncol Pharm Pract. 2020, 26:256-8. 10.1177\/1078155219877234","journal-title":"J Oncol Pharm Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew281","article-title":"Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer","volume":"55","author":"Law-Ping-Man S","year":"2016","unstructured":"Law-Ping-Man S, Martin A, Briens E, Tisseau L, Safa G. Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology. 2016, 55:2087-9. 10.1093\/rheumatology\/kew281","journal-title":"Rheumatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13818","article-title":"ADAMTSL5 is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab","volume":"31","author":"Nonomura Y","year":"2017","unstructured":"Nonomura Y, Otsuka A, Ohtsuka M, Yamamoto T, Dummer R, Kabashima K. ADAMTSL5 is upregulated in melanoma tissues in patients with idiopathic psoriasis vulgaris induced by nivolumab. J Eur Acad Dermatol Venereol. 2017, 31:e100-1. 10.1111\/jdv.13818","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0249","article-title":"Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma","volume":"151","author":"Ohtsuka M","year":"2015","unstructured":"Ohtsuka M, Miura T, Mori T, Ishikawa M, Yamamoto T. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol. 2015, 151:797-9. 10.1001\/jamadermatol.2015.0249","journal-title":"JAMA Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2012.01544.x","article-title":"Coexpression of CCR6 and CD146 (MCAM) is a marker of effector memory T-helper 17 cells","volume":"39","author":"Kamiyama T","year":"2012","unstructured":"Kamiyama T, Watanabe H, Iijima M, Miyazaki A, Iwamoto S. Coexpression of CCR6 and CD146 (MCAM) is a marker of effector memory T-helper 17 cells. J Dermatol. 2012, 39:838-42. 10.1111\/j.1346-8138.2012.01544.x","journal-title":"J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/52136-a-case-of-de-novo-psoriasis-secondary-to-nivolumab-in-a-patient-with-metastatic-renal-cell-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:00Z","timestamp":1707507060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/52136-a-case-of-de-novo-psoriasis-secondary-to-nivolumab-in-a-patient-with-metastatic-renal-cell-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.15703","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,16]]}}}